Souhaitez-vous accéder aux communiqués récents ?

Inside information: Suominen launches three-year profitability improvement program and introduces new operating model and leadership team

Commencement of a new plan period in the share-based Long-Term Incentive Plan for management and key employees

Suominen Oyj:n tilinpäätöstiedote (tilintarkastamaton) 1.1. –31.12.2025 Epätyydyttävä tulos haastavassa toimintaympäristössä

Suominen Corporation’s Financial Statements Release (unaudited) for January 1 – December 31, 2025:Unsatisfactory performance in a challenging environment

Virtualware, a pioneer in 3D-driven software, has appointed Canadian nuclear engineer Stephanie Smith, P. Eng., to its international advisory board.

ENDEAVOUR ACHIEVES GUIDANCE & DECLARES RECORD H2-2025 DIVIDENDFY-2025 production of 1,209koz at AISC of ~1,435/oz l H2-2025 dividend of $200m l >$1bn shareholder returns programme OPERATIONAL...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN...

2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER1 and business earnings per share (EPS)2 of €1.53 Pharma...

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive...